Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1191 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-07-24
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 62.10 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 82.56 | Oscillator | Sell |
| Williams %R (14) | -12.50 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.07 (Hist -0.02) | Oscillator | Sell |
| Average Directional Index (14) | 19.67 (+DI 21.3 / -DI 19.7) | Trend | Neutral |
Current price $24.99
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 25, 23 | Keybanc |
| EMA 20 | 24.94 | MA | Buy |
| SMA 20 | 24.93 | MA | Buy |
| EMA 50 | 24.25 | MA | Strong Buy |
| SMA 50 | 24.90 | MA | Buy |
| SMA 200 | 16.92 | MA | Strong Buy |
| downgrade |
| Overweight |
| Sector Weight |
| Jun 21, 23 | Stifel | maintain | Hold | Hold |
| May 4, 23 | Morgan Stanley | maintain | Underweight | Underweight |
| Feb 22, 23 | Morgan Stanley | maintain | Underweight | Underweight |
| Jan 6, 23 | Morgan Stanley | maintain | Underweight | Underweight |
| Nov 3, 22 | Keybanc | maintain | Overweight | Overweight |
| Oct 11, 22 | Morgan Stanley | maintain | Underweight | Underweight |
| Aug 10, 22 | Keybanc | maintain | Overweight | Overweight |
| Jul 18, 22 | Stifel | maintain | Hold | Hold |
Stock news · updated daily
Sintx Technologies (NASDAQ: SINT - Get Free Report) and Avanos Medical (NYSE: AVNS - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Insider and Institutional Ownership 18.4% of Sintx Technologies
Bank of America Corp DE grew its position in shares of Avanos Medical, Inc. (NYSE: AVNS) by 30.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 110,978 shares of the company's stock after purchasing an additional 25,767 shares during the quarter.
BlackRock Inc. purchased a new position in Avanos Medical, Inc. (NYSE: AVNS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,468,794 shares of the company's stock, valued at approximately $185,824,000. BlackRock Inc. owned 15.94% of Avanos Medical at the end of
NEW YORK--(BUSINESS WIRE)--Sterlington advises Avanos Medical management team on $1.27 billion acquisition.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| May 5, 2026 | 0.16 | 0.22 | Beat 37.5% | $182.2M |
| Feb 24, 2026 | 0.24 | 0.29 | Beat 20.8% | $180.9M |
| Nov 5, 2025 | 0.12 | 0.22 | Beat 83.3% | $177.8M |
| Aug 5, 2025 | 0.18 | 0.17 | Miss -5.6% | $175.0M |
| May 6, 2025 | 0.19 | 0.26 | Beat 36.8% | $167.5M |
| Feb 26, 2025 | 0.40 | 0.43 | Beat 7.5% | $179.6M |
TTM vs. 5-year historical average (annual ratios)
| Metric | AVNS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -16.7x | 53.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 25.0x | EPS est. 1.00 | Discount |
| Price / Book | 1.5x | 0.9x | Elevated |
| Price / Sales | 1.6x | 1.5x | In line |
| EV / EBITDA | -57.6x | 9.6x | Discount |
| Return on equity | -8.9% | — | Weak |
| Gross margin | 48.6% | 54.0% | In line |
| Debt / Equity | 0.18 | 0.18 | Conservative |
| Piotroski / Altman Z | 4/9 | Z 2.30 | Grey zone |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 15-12G | Aug 6, 2026 | 2026-08-06 08:33:21 | View |
| S-8 POS | Jul 31, 2026 | 2026-07-31 14:51:52 | View |
| SC 13G | Jul 31, 2026 | 2026-07-31 09:57:15 | View |
| 8-K | Jul 30, 2026 | 2026-07-30 16:05:40 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:40:36 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:39:58 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:39:22 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:38:24 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:37:40 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:37:04 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 27, 26 | Delgado Sigfrido | officer: SVP, Operations | A-Award | 54,886 | — |
| Jul 27, 26 | Delgado Sigfrido | officer: SVP, Operations | D-Return | 37,520 @ $13.69 | $513.6K |
| Jul 27, 26 | Delgado Sigfrido | officer: SVP, Operations | D-Return | 21,914 @ $15.24 | $334.0K |
| Jul 27, 26 | Delgado Sigfrido | officer: SVP, Operations | D-Return | 54,886 @ $25.00 | $1.37M |
| Jul 27, 26 | Galovan Scott Michael | officer: SVP, Chief Financial Officer | A-Award | 96,121 | — |
| Jul 27, 26 | Galovan Scott Michael | officer: SVP, Chief Financial Officer | D-Return | 21,038 @ $15.24 | $320.6K |
| Jul 27, 26 | Galovan Scott Michael | officer: SVP, Chief Financial Officer | D-Return | 96,121 @ $25.00 | $2.40M |
| Jul 27, 26 | Galovan Scott Michael | officer: SVP, Chief Financial Officer | D-Return | 69,630 @ $13.69 | $953.2K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure